More from ASCO 2023 [1] [2].
"Patients in the ENZAMET trial (n = 1125) were randomized 1:1 to arm A, the control arm consisting of TS plus a standard non-steroidal antiandrogen ([NSAA] bicalutamide, nilutamide, or flutamide), or enzalutamide at 160 mg per day plus TS in arm B. "
"The 5-year OS rates were 81% and 66% for those with low-volume mHSPC who did not receive docetaxel with enzalutamide and NSAA treatment, respectively, and 57% and 47% for those with high volume."
-Patrick
see also: urologytimes.com/view/clini...
TS=testosterone suppression
Developments in the nanoparticle world and how to determine and predict chemo benefits in MHSPCFirst Follow Up on my Treatment in AustraliaA look at the next generation of Androgen Receptor therapies--AR Degraders/PROTACSDevelopments in the Continued Search for a Prostate Cancer Vaccine...
My reaction to Crestor & Nubeqa combo. I need to make some adjustments. This study says simvastatin is best against APC. Your thoughts? 
